The use of JAK inhibitors in the treatment of Progressive Systemic sclerosis

Abstract

Systemic sclerosis is a connective tissue disorder characterized by fibrosis. Patients may have restricted movement of the joints, Raynaud's phenomenon, self-amputation of the digits, dyspnea, and upper gastrointestinal symptoms. Excessive production of extracellular matrix (ECM) proteins such as type I collagen via transforming growth factor β (TGF β) are thought to be responsible for the fibrosis.¹

This article is protected by copyright. All rights reserved.

http://ift.tt/2HfJg2P